Caris Life Sciences, Inc.
Financials
Valuation Metrics
Caris Life Sciences, Inc.'s Market Cap is $9.07B. At end of 2025 it was $45.11B. Ranked #923 of 3,118 in US market (top 30%), #289 of 1,474 on NASDAQ (top 20%), #45 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.07B | US#923/3,118 Sec#45/265 |
| Revenue | $990M | US#1,875/3,118 Sec#52/265 |
| Net Income | $105M | US#1,595/3,118 Sec#55/265 |
| Total Assets | $1.23B | US#2,371/3,118 Sec#82/265 |
| Net Assets | $592M | US#2,104/3,118 Sec#97/265 |
| Employees | 1,846 | US#1,720/3,118 Sec#43/265 |
| Value | ||
| P/E | 86.31x | US#2,076/3,118 Sec#61/265 |
| P/B | 15.33x | US#2,749/3,118 Sec#209/265 |
| P/S | 9.17x | US#2,697/3,118 Sec#118/265 |
| EV/EBITDA | 51.16x | US#2,369/3,118 Sec#73/265 |
| FCF Yield | 1.37% | US#2,131/3,118 Sec#75/265 |
| Profitability | ||
| ROE | 17.77% | US#719/3,118 Sec#36/265 |
| ROA | 8.55% | US#593/3,118 Sec#40/265 |
| Op. Margin | 15.49% | US#1,155/3,118 Sec#49/265 |
| Revenue Growth | 104.87% | US#89/3,118 Sec#32/265 |
| Financial Health | ||
| Debt Ratio | 107.80% | US#1,166/3,118 Sec#168/265 |
| Total Debt | $452M | US#1,908/3,118 Sec#65/265 |
| FCF | $124M | US#1,640/3,118 Sec#59/265 |
| Cash | $691M | US#880/3,118 Sec#40/265 |
| Current Ratio | 5.53x | US#424/3,118 Sec#131/265 |
| Net Debt/EBITDA | -1.38x | US#244/3,118 Sec#16/265 |
| Performance | ||
| 1Y Return | 6.72% | US#1,480/3,118 Sec#127/265 |
| 1M Return | 13.43% | US#615/3,118 Sec#42/265 |
| From 52W High | -12.05% | US#495/3,118 Sec#35/265 |
| 1Y MDD | -53.34% | US#2,519/3,118 Sec#181/265 |
| Trading | ||
| Volume | 2,826,686 shares | US#673/3,118 Sec#53/265 |
| Trading Value | $93M | US#873/3,118 Sec#46/265 |
| Per Share | ||
| EPS | $0.37 | US#1,928/3,118 Sec#65/265 |
| BPS | $2.09 | US#2,562/3,118 Sec#177/265 |
Company Info
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.